The UK Medicines and Healthcare products Agency (MHRA) has given regulatory approval to Codagenix Inc.’s vaccine COVI-VAC to begin phase 1 clinical trial in London to determine its safety and immunogenicity in 48 volunteers between the ages of 18 and 30. COVI-VAC is a live-attenuated vaccine with an identical structure to wild-type SARS-CoV-2, but it is slower to replicate. It requires a single dose and is administered intranasally.
Countering Misinformation & Disinformation: Practical Training for Organizations
Practical skills to detect, verify, and respond across an evolving information landscape